Show simple item record  

dc.contributor.authorBrown, Charisen_NZ
dc.contributor.authorLao, Chunhuanen_NZ
dc.contributor.authorLawrenson, Rossen_NZ
dc.contributor.authorTin Tin, Sandaren_NZ
dc.contributor.authorSchaaf, Michelleen_NZ
dc.contributor.authorKidd, Jacquieen_NZ
dc.contributor.authorAllan-Moetaua, Anneen_NZ
dc.contributor.authorHerman, Josephineen_NZ
dc.contributor.authorRaamsroop, Reenaen_NZ
dc.contributor.authorCampbell, Ianen_NZ
dc.contributor.authorElwood, Marken_NZ
dc.date.accessioned2018-06-05T04:47:33Z
dc.date.available2017-12-15en_NZ
dc.date.available2018-06-05T04:47:33Z
dc.date.issued2017en_NZ
dc.identifier.citationBrown, C., Lao, C., Lawrenson, R., Tin Tin, S., Schaaf, M., Kidd, J., … Elwood, M. (2017). Characteristics of and differences between Pasifika women and New Zealand European women diagnosed with breast cancer in New Zealand. New Zealand Medical Journal, 130(1467), 50–61.en
dc.identifier.issn0028-8446en_NZ
dc.identifier.urihttps://hdl.handle.net/10289/11876
dc.description.abstractAIM: Breast cancer in New Zealand-based Pasifika women is a significant issue. Although Pasifika women have a lower incidence of breast cancer compared to New Zealand European women, they have higher breast cancer mortality and lower five-year survival. The aim of this study was to describe the characteristics and tumour biology of Pasifika women and to compare New Zealand European women to identify what factors impact on early (Stage 1 and 2) vs advanced stage (Stage 3 and 4) at diagnosis. METHOD: Data on all Pasifika and New Zealand European women diagnosed with breast cancer (C50) during the period 1 June 2000 to 31 May 2013 was extracted from the Auckland and Waikato Breast Cancer Registries. Descriptive tables and Chi-square test were used to examine di erences in characteristics and tumour biology between Pasifika and New Zealand European women. Logistic regression was used to identify factors that contributed to an increased risk of advanced stage at diagnosis. RESULTS: A significantly higher proportion of Pasifika women had advanced disease at diagnosis compared to New Zealand European women (33.3% and 18.3%, respectively). Cancer biology in Pasifika women was more likely to be: 1) HER2+, 2) ER/PR negative and 3) have a tumour size of ≥50mm. Pasifika women live in higher deprivation areas of 9–10 compared to New Zealand European women (55% vs 14%, respectively) and were less likely to have their cancer identified through screening. Logistic regression showed that if Pasifika women were on the screen-detected pathway they had similar odds (not sig.) of having advanced disease at diagnosis to New Zealand European women. CONCLUSION: Mode of detection, deprivation, age and some biological factors contributed to the di erence in odds ratio between Pasifika and New Zealand European women. For those of screening age, adherence to the screening programme and improvements in access to earlier diagnosis for Pasifika women under the current screening age have the potential to make a substantial di erence in the number of Pasifika women presenting with late-stage disease.en_NZ
dc.format.mimetypeapplication/pdf
dc.language.isoen
dc.rights© NZMA. Used with permission
dc.titleCharacteristics of and differences between Pasifika women and New Zealand European women diagnosed with breast cancer in New Zealanden_NZ
dc.typeJournal Article
dc.relation.isPartOfNew Zealand Medical Journalen_NZ
pubs.begin-page50
pubs.elements-id216098
pubs.end-page61
pubs.issue1467en_NZ
pubs.publication-statusPublisheden_NZ
pubs.volume130en_NZ
dc.identifier.eissn1175-8716en_NZ


Files in this item

This item appears in the following Collection(s)

Show simple item record